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Practical Implications
Increased exposure to particulate contaminants has been linked to deleterious health and 
well-being outcomes. This study provides an in vitro method to quantify the administered dose of A
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particulates deposited on the facial mucosa on an individual basis. With the merits of low cost and 
timely processing, this method enlightens the future design of personalized environment control 
and protection strategies. 
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Abstract 
Exposure to particulate contaminants can cause serious adverse health effects. Deposition on 
the facial mucosa is an important path of exposure, but it is difficult to conduct direct dose 
measurement on real human subjects. In this study, we propose an in vitro method to assess the 
administered doses of micron-sized particles on the eyes and lips in which computed tomographic 
scanning and three-dimensional printing were used to create a model that includes a face, 
oropharynx, trachea, the first five generations of bronchi, and lung volume. This realistic model of 
a face and airway was exposed to monodispersed fluorescent particles released from an incoming 
jet. The administered dose of particles deposited upon the eyes and lips, as quantified by 
fluorescence intensity, was determined via a standard wiping protocol. The results show that, in 
this scenario, the administered doses normalized by source were 2.15%, 1.02%, 0.88%, 2.13%, 
and 1.55% for 0.6-µm, 1.0-µm, 2.0-µm, 3.0-µm, and 5.0-µm particles, respectively. The 
administered dose of large particles on the mucosa within a given exposure time has great 
significance. Moreover, the lips suffer a much greater risk of exposure than the eyes and account 
for more than 80% of total facial mucosa deposition. Our study provides a fast and economical 
method to assess the administered dose on the facial mucosa on an individual basis.
Key words: mucosal exposure; in vitro; CT scanning; 3D printing; deposition; occupational health
1. Introduction
Public and occupational exposure to particulate contaminants is considered a common A
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threatening factor to human health1,2. Deposition on the mucosa, along with inhalation and 
deposition on the skin, is a major pathway for intake of particles into the body, which may result 
in a series of adverse health outcomes, such as irritation, inflammation, and chronic disease3–6. 
Intact skin poses an effective barrier against the absorption of particles, but the thin epidermal 
layers of mucosal surfaces are less protective. Epidemiologic studies have reported that burning, 
dryness, and itching of the eyes are among the most common symptoms from occupant 
complaints7,8. Prolonged exposure to environmental particulate pollution can cause severe 
disease9,10. An accurate and quantitative measure of the causal relationship between exposure and 
health outcomes would certainly benefit the development of effective control strategies, but such a 
measure is beyond the resolution of common epidemiologic studies. In vitro methods11,12 such as 
cell13 or animal models14,15 can implement partial pathological evidence of damage to genes, 
tissues, and organs, but their lack of individual susceptibility limits definitive conclusions for 
population subgroups. In contrast, biomarkers that indicate oxidative stress, inflammation, 
thrombosis, and many other health outcomes reflect individual susceptibility16,17, but uncertainty 
remains due to disturbances from uncontrolled confounders. Nevertheless, decades of medical 
studies have supplied massive evidence for exposure limits to particulate contaminants, especially 
in occupational scenarios. For instance, exposure to household and ambient fine particulate matter 
(PM2.5) should not exceed 5.9 µg/m3 for a theoretical minimum health risk1. The exposure in 
practice is often interpreted as the spatial average of local particle concentrations at chosen 
sampling locations or as the temporal average of total particle counts obtained near body intake 
pathways. Neither measure is equivalent to the dose of particles administered to the facial mucosa 
or to the associated health outcomes due to factors such as the deposition efficiency, the proximity 
to the contaminant source, and the particle distribution in room air3.
Until recent years, it was impossible to measure the administered dose, that is, the number of 
particles that make direct contact with the body’s absorption barriers and are therefore available 
for absorption. For respiratory issues, individual in vitro models18,19 have been constructed to 
simulate the dose of particles administered to anatomically correct airways with a fast-developing 
computed tomographic (CT) technique20–23. These models make it feasible to assess the dose on an A
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individual basis, which parallels the need for personalized environment control strategies24. In 
addition to evidence from medical studies, an assessment of the actual administered dose would 
benefit our understanding of the causal relationships among exposure, the dose, and the associated 
health outcomes. However, studies that have used anatomically correct models have focused 
mainly on inhalation25–28. We were unable to find a mucosa dose assessment based on an in vitro 
model.
In this study, a new method is proposed to assess the administered dose on human facial 
mucosa. Based on CT images from a healthy volunteer, a realistic face and airway model that 
included a face, an oropharynx, a trachea, the first five generations of bronchi, and lung volume 
was obtained via three-dimensional (3D) printing and connected to a pump to simulate 
steady-state inhalation. Micron-sized monodispersed fluorescent particles were generated by TSI 
VOAG 3450 and monitored by TSI APS 3321. Administered doses on eyes and lips were 
quantified as the cumulative deposition mass, as measured via a wiping method and calculated via 
fluorescence intensity-mass concentration correlation curves. This in vitro method provides a fast 
and economic means to assess administered dose on facial mucosa.
2. Methods
2.1 In vitro face and airway model
An in vitro model replicates only a portion of human physiologic functions. In this study, the 
model represented the detailed geometry of the face and airway. The geometry was obtained by 
processing the CT images of a healthy 34-year-old male volunteer with no history of smoking or 
lung disease. Imaging was conducted in the supine position with a Philips Brilliance iCT scanner 
(Koninklijke Philips N.V., Netherlands). The obtained data were helical with reconstructed axial 
slices 1.5 mm thick; and 560 two-dimensional slices covered the geometry from head to 
diaphragm (Figure 1a and 1b). The regions of interest were identified and extracted with 
commercial software (Materialise Mimics 17.0, Ann Arbor, MI). The current imaging resolution 
allows modeling up to the fifth generation of bronchi. The terminal bronchi were trimmed along 
planes normal to the centerline, where the airflow enters the lung volume formed by the lungs’ 
boundary. Figure 1c shows the extracted geometry.A
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A realistic face and airway model was printed via the stereolithographic appearance 3D 
printing technique. A photosensitive resin SPR6000 was used (XJRP, Xi’an, China), with a 
surface roughness of less than 0.1 mm and an electrostatic capacitance of less than 0.002 µC (<0.4 
m/s flow speed; 25°C, 50% relative humidity). The model was printed in three parts: the face with 
the central airway; the left lung volume with G1-G5 left upper lobe and left lower lobe; and the 
right lung volume with G1-G5 right upper lobe, right middle lobe, and right lower lobe. For 
sampling and cleaning purposes, the left and right lung volumes were designed to be separated 
into two parts, both of which can be connected and sealed externally to become airtight. Figure 2 
shows the face and airway model under sealed and separated conditions.
The thickness of the model boundary was 3.0 mm. One 5.0-mm conducting tube was added to 
the outer side of each lung volume, respectively, to connect with the pump to generate the 
inhalation airflow. Figure 2 shows the 5.0-mm sampling hole added to the bottom of each lung 
volume.
The financial and time costs to make such a model are low, so it is feasible to conduct a series 
of measurements or numerical simulations for a population subgroup. This study used one 
individual case to illustrate the procedure of measurement and result analysis.
2.2 Experimental setup
The experiment was conducted in a ventilation cabinet (1.8 × 0.7 × 1.4 m). The ventilation 
system was run to exhaust any particles before each trial. Figure 3 presents detailed information on 
the experimental setup. A monodispersed particle jet was generated continuously with a vibrating 
orifice aerosol generator model (VOAG 3450, TSI, USA). A liquid solution of ultrapure water and 
sodium fluorescein (C20H10Na2O5) was injected into the VOAG with a syringe pump at a 
predetermined volume flow rate. The solution jet was released through a small orifice (diameter, 
20 µm). The jet breaks up into uniform droplets when the orifice vibrates, and the size of the 
droplets generated was dependent on the operating frequency and the syringe pump flow rate. For 
this measurement, the orifice operating frequency ranged from 67.0 to 75.0 kHz, and the syringe 
pump flow rate ranged from 8.3 to 12.0 mL/h. We generated 0.6-µm, 1.0-µm, 2.0-µm, 3.0-µm, 
and 5.0-µm monodispersed particles that were totally evaporated from the initial monodispersed A
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droplets in a drying cylinder. The particle density was 1530 kg/m3. The circular opening of the 
cylinder carries the airflow jet and the particles toward the model of the face and airway.
The Aerodynamic Particle Sizer Spectrometer Model APS 3321 (TSI, USA) was used to 
monitor the particulate size distribution and concentration in real time. The monodispersity of the 
particle size ranged from 78.5% to 93.3%, and the geometric standard deviation was less than 1.2. 
After the concentration stabilized, the spectrometer was disconnected, and the model was put 
inside the cabinet. The distance from the nose of the model to the outlet of the particle jet was kept 
as 0.2 m. A mouth-breathing man was simulated during the measurement when the nose was well 
sealed. The model can mimic patients with symptoms such as a runny nose or workers performing 
heavy exercise29. The continuous inhalation airflow of 11.0 ± 1.0 L/min provided by the vacuum 
pump was similar to the standard flow rate of a man while standing30. The vacuum pump was 
connected to the outlets on both sides of the lungs. The administered doses of eyes and lips were 
represented as the accumulated mass of particles deposited on the target surface during the 
exposure time. The ventilation system was turned off during the measurements. Trials for each 
particle size were repeated three times to obtain an average value.
2.3 Wiping method and verification
Administered doses on left eye, right eye, and lips were quantified via the wiping method 
developed by Da et al.31. Fluorescent particles on the target regions were wiped more than five 
times with cotton buds humidified in 20 cm3 of water (1:1000 of 20% liquid ammonia in ultrapure 
water) and transferred into samplers. This process was repeated three times per case for each 
sampling region. The fluorescence intensity was detected with a fluorophotometer Fluoro Max-4 
(Horiba, Japan), and the particle mass was calculated on the basis of the calibrated relationship 
between the fluorescence intensity and the mass concentration (Figure 4). The total mass of three 
repeated samples was the administered dose for the target region.
The efficiency of the wiping method was quantified on the basis of the particle transfer loss 
rate. A certain amount of sodium fluorescein was weighed with a high-precision balance (Satorius 
MC210P, Germany) and dissolved into the ammonia solution. A fixed volume of fluorescent 
solution was then dropped onto a sample surface of the same material as the model. After natural A
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drying of fluorescent solution in a clean environment, the fluorescence intensity was measured, 
and the particle transfer loss rate was calculated as 44.4% ± 6.7%, which indicates a high rate of 
particulate adhesion on the material surface. We therefore used aluminum foil, which has excellent 
collection efficiency and low static electricity to cover the eyes and lips (Figure 2), which limited 
the transfer rate loss to 12.5% ± 5.2%.
Our study focuses on exposure to monodispersed fine particles with aerodynamic diameters 
of 0.6, 1.0, 2.0, 3.0, and 5.0 µm. Because the fluorescence intensity increased with the particle 
mass and size, we extended the exposure time for smaller particles to facilitate the collection of 
samples within the range of a standard curve. Table 1 shows the experimental levels for each 
particle size.
2.4 Method uncertainty
To the best of our knowledge, no published studies have measured the administered dose on 
the eyes and lips of real human subjects. We were thus unable to calibrate our in vitro model with 
a quantitative in vivo method, if any exists. The major limitation of our model is its obvious lack 
of biological properties of real human subjects.
2.4.1 Eyelashes
Real-time monitoring to quantify the actual dose in human subjects presents a challenge, so 
compromises were necessary during the study design process. Our method did not consider 
eyelashes or blinking, which may have greatly reduced the actual doses. The limited availability of 
human eyelids for sampling means that studies remain scarce despite recent advances in eyelash 
research32. No in vivo studies of human eyelash aerodynamics have yet been published. Only one 
study has applied an in vitro method to explore in detail the aerodynamic features around the 
eyes33. In that study, the model geometry was idealized into an ocular surface with surrounding 
eyelashes and was isolated from the rest of the body. To determine the eyelashes’ effects on 
deposited particles, fluorescent droplets with an average size of 10 µm were injected with a 
commercial humidifier. An absorbent paper disc was applied to the ocular surface to intercept 
incoming droplets. The fluorescence intensity corresponded to the number of droplets deposited. 
Five eyelash lengths L were used, and the ratios of the eyes’ width W to the length of the eyelashes A
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were measured as 0.0 (without eyelashes), 0.1, 0.2, 0.4, and 0.8. Table 2 lists the relationship 
between L/W and the fluorescence intensity.
The human eyelash normally ranges from 8.0 to 12.0 mm long34. The average eye width of 
the volunteer in our study was 26.7 mm. Amador et al. found that the administered doses of 
10.0-μm particles will be overestimated by 25% to 40% in mammals if the eyelashes are 
neglected. 
2.4.2 Mucosal lining fluid
Our model did not include goblet cells, mucus secretory cells, or submucosal glands to 
produce mucosal lining fluid (i.e., mucus)35. Mucin is the main structural component of mucus; 
these components interact with each other and with other components of mucus to form a 
meshlike structure12,36,37. In addition to this meshlike structure, mucus captures foreign particles 
via an adhesion effect. However, the density, viscosity, and elasticity of human mucus are not 
evident in the literature, not to mention the mucin-based meshlike structure within it. As a result, 
we were unable to find any valid simulant. Moreover, some studies38,39 have suggested that the 
efficient defense proteins in saliva near the mucosal surfaces of the oral cavity contribute to inhibit 
influenza viruses. Whether the mucin from real-life mucus plays a role in defending against 
illness, infection, and/or poisoning requires further investigation. In addition, the main component 
of mucus is water (up to 95% by weight), so the wetting of real mucosa differs from that in our in 
vitro model. By neglecting mucus, we were unable to mimic the humid environment along the 
mucosa’s boundary layer, which adds uncertainty to the deposition of hygroscopic particles40.
2.4.3 Body heat release
Our method simplifies the exposure process into an isothermal scenario. The temperature of 
the model’s skin was 6°C to 10°C lower than that of human skin. The consequent variation in 
thermophoresis on micron-sized particles is negligible41. Nevertheless, when in a state of thermal 
comfort, the human body dissipates 30% to 35% of its metabolic heat via convection. The human 
convective boundary layer (i.e., the body plume) interacts with the surrounding airflows and 
modifies their movement around the human microenvironment 42. The body plume can entrain 
particles from the ambient air into the breathing zone43–45, where the plume velocity can reach A
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0.15 to 0.30 m/s. In our study, the particle-laden jet had an initial velocity of 0.94 m/s. The 
centerline velocity decreased to about 0.86 m/s when the jet met the model, as estimated with the 
free jet theory46. The jet’s momentum is much stronger than that of the plume flow, so we ignored 
heat release under the current measurement setup. It should be noted that the plume flow plays an 
important role in exposure when source of contamination is sufficiently near.
2.4.4 Blank measurement
In addition to neglecting the biological features of real human subjects, we also estimated the 
uncertainty induced by measurement with the fluorescent tracer. We measured the differences in 
intensity before and after exposure to pure water droplets to evaluate the influence of background 
particles. The experimental setup was the same as shown in Figure 3. The presence of only a slight 
difference in Figure 5 indicates that the deposition of environmental particles can be neglected.
The fluorescence that remains on the surface after each test will increase the uncertainty. We 
thus cleaned the model by immersing it in a tank filled with a mixture of pure water and detergent 
for 24 hours and measured the intensity of the eyes and lips before each trial. The fluorescence 
intensity of the auxiliary solution (i.e., pure water and ammonia) was also tested to exclude any 
influence on the fluorescent solution. The results are shown in Figure 6 and were used as a 
benchmark for the experiments’ reliability. If the fluorescence intensity of each measurement was 
one magnitude greater than the background, the fluorescent residue was considered to have little 
effect on the experimental results.
3. Results
3.1 Mucosal deposition
The mucosal exposure ratio is defined by the ratio of the administered dose wi in the total 
source release w0.
                                                                     𝑤0 = 𝐶𝑠·𝑞·Δ𝑡·𝑉𝑝                                                           (2)
Where
, total source release (g);𝑤0
CS, particle concentration at the opening of the jet flow (N/m3);A
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, inhalation airflow rate (m3/s);𝑞
, total exposure time (s);Δ𝑡
, particulate volume (m3).𝑉𝑝
Administered doses of eyes and lips were normalized by the total source release (Figure 7). 
As shown in Figure 8, the mucosal deposition rate ranged from 2.13% ± 0.63% to 0.88% ± 0.56% 
(g/g) for 0.6-µm to 5.0-µm particles, and the 0.6-µm, 3.0-µm, and 5.0-µm particles showed a high 
mucosal deposition rate due to the relaxation time of the various size particles. A longer relaxation 
time makes larger particles easier to separate with airflow during transportation than smaller 
particles, and it means that they are less likely to be inhaled and deposited on the surface. The 
opposite is true for smaller particles. Hence, the smallest and largest particles both resulted in a 
high dose to the facial mucosa.
Figure 8 also indicates the distribution of particle deposition on the eyes and lips. We 
conclude that the lips contribute to more than 80% of the administered dose to the total facial 
mucosa for particles between 0.6 and 5.0 µm. We suspect that the lips’ large surface area relative 
to the eyes is the reason for the high administered dose. The effects of surface area on the left eye, 
right eye, and lips are discussed further below.
3.2 Individual difference assessment
The administered dose index ADi named as particle deposit on unit surface in unit time (Eq. 
3).
                                                              𝐴𝐷𝑖 =
𝑤𝑖
𝐴·𝑡
      (𝑚𝑔/𝑚2·𝑠)                                                (3)
Where A is the area of the lips, the left eye, and the right eye (m2).
Figure 9 shows the calculation for the administered dose index for each particle size. The 
difference in the doses administered to the left eye and right eye is less obvious, so the difference 
between the eyes in Figure 8 more likely comes from the surface area, which varies among 
subjects. Generally speaking, lips had the largest administered dose for particles between 0.6 and 
5.0 µm. When the particle size was less than 1.0 µm, the dose to the lips was only 1.28 times that 
of the eyes. As the particle size increased, the ratio also showed a significant increase. For A
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particles larger than 3.0 µm, the administered dose indexes of the eyes and lips were 30.7 ± 5.66 × 
10-4 mg/m2· s and 83.40 ± 4.39 ×10-4 mg/m2· s, respectively. Particle deposition on the lips was 
2.55 times that on the eyes, and the figure increased to 3.22 with the use of 5-μm particles. The 
results reveal that the lips have a greater exposure risk, especially with large particles.
3.3 Influence of inhalation airflow
We measured the administered dose of various particle sizes without inhalation to quantify the 
effect of inhalation airflow. All parameters were the same as those listed in Table 1 except that the 
pump was turned off.
Pi indicates the administered dose of the eyes and lips ( ) to the dose of the total facial 𝑤𝑖
mucosa (w). Figure 10 shows the results,
                                                                             𝑃𝑖 =
𝑤𝑖
𝑤                                                                          (1)
Where 
is the deposition percentage of the left eye ( ), right eye ( ), and lips ( ) (%);𝑃𝑖 𝑃𝑙𝑒 𝑃𝑟𝑒 𝑃𝑙
 is the administered dose on the left eye ( ), right eye ( ), and lips ( ) (g);𝑤𝑖 𝑤𝑙𝑒 𝑤𝑟𝑒 𝑤𝑙
 is the administered dose on the total facial mucosa,  =  +  +  (g).𝑤 𝑤 𝑤𝑙𝑒 𝑤𝑟𝑒 𝑤𝑙
The influence of inhalation airflow increased as the particle size decreased. For particles 
between 0.6 and 2.0 µm, the influence of inhalation airflow was less than 5.0%, but for 3.0-μm 
and 5.0-μm particles, the ratio dropped below 1.0%. Because the sink flow into the mouth has 
little effect on the airflow field outside the mouth, inhalation airflow may not be necessary to 
measure mucosal deposition of large particles near their source.
4. Discussion
The mucosal surface is susceptible because its barriers are less effective than those of intact 
skin9. Although mucosa lining fluid can compensate and trap some foreign particles with its 
adhesive and viscoelastic layers, others may penetrate the mucosa into the human circulatory 
system.
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The published clinical studies can help to understand the response of the mucosal dose to 
particulate contaminants. Chu et al. found a significant connection between the PM2.5 
concentration and oral cancer based on a large sample size6. Exposure to heavy metal pollutants 
such as arsenic, nickel, and chromium increases the risk of oral cancer. Veres4 concluded that 
inhaled environmental allergens may induce aberrant activation of immune cells in the airway 
mucosa, resulting in allergic airway disease. Studies of the side effects of drug delivery have also 
shown that penetration of particulates through mucus poses a potential risk to human health12. 
Nanocarriers are normally used in drug delivery because they can penetrate quickly through 
mucus to reach the underlying cells. Takeuchi et al. believed that particle size plays an important 
role in particle movement in mucus47. They examined the ability of chitosan-coated liposomes to 
penetrate mucus after oral administration of liposomes in rats. Their results showed that 100-nm 
liposomes had the best penetration ability. Hadrup et al. 9 discussed the toxicity of nanoparticles 
after dermal and mucosal surface exposure. Exposure to silver particles can cause localized argyria 
and eye irritation, and a 7-g dose of silver nitrate (∼64 mg silver/kg body weight) is fatal to 
humans.
The administered doses on eyes and lips in our experimental setup were much lower than the 
fatal dose reported by Hadrup et al.9, and the particle concentrations in our experiment could be 
much lower than those in the actual industrial environment under a specific production process. 
The average concentration during arc welding is 1.42 × 107 particles/cm3 at 4.8 cm from the 
emission source48. This is 3.5 million times higher than the concentration in our experiment (4.0 
particles per cm3). Welding particles, mostly between 14 nm and 10 µm, are highly toxic heavy 
metals49. Measurements by Zimmer and Biswas revealed that the average particle concentration in 
breathing zone during welding can reach 5 mg/m3 48. The dose thus administered to the facial 
mucosa during welding may cause significant damage if the workers fail to use effective 
protection.
Exposure to 5 µg/m3 of particles between 1.0 and 7.0 µm can increase irritation in the eyes, 
nose, and throat7. Long-term exposure to such particulate contaminants increases mucosa 
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permeability and makes penetration of the mucus a more effective pathway. More studies are 
needed to determine the chronic health effects after long-term mucosa exposure.
One important influence on the administered dose is the proximity to the source. In our study, 
the distance between the susceptible individual and the particle source was 0.2 m, which falls 
within the range of the direct deposition route or the short-range airborne route, if the source is an 
index patient with a respiratory infection like tuberculosis or influenza50. In our measurements, 
particles between 0.6 and 5.0 µm may represent the expiratory aerosols that carry influenza 
viruses51. The particle-laden jet is also similar to a snapshot of the coughing or breathing airflow 
from the host of a pathogen, when the puff flow is fully developed52. Our results indicate that 
mucosal deposition acts as an important pathway, especially for particles with larger sizes in terms 
of dosage. Nevertheless, the viability of pathogens after deposition on facial mucosa may be 
challenged by factors such as the sharp temperature decrease in the expired droplets, impaction 
upon deposition, and defense proteins in the mucus53. Detailed studies that include actual 
pathogens or their surrogates such as bacteriophages could help us understand some of these 
complexities.
In addition to mucosal deposition, inhalation exposure is also an important exposure route. 
We plan to further quantify the inhalation exposure of airborne particles based on the workbench 
of this study. Although our model includes neither epithelial cells to absorb particles nor cilia to 
activate the mucus clearance mechanism, we aim to compensate with existing theoretical and 
anatomical models to calibrate compartmental deposition along the airway. Because lower airway 
exposure contributes to most health risks, the overall administered dose of particles that penetrate 
the lower airway from the sixth generation of the bronchi will be measured. When compared to the 
administered dose on the facial mucosa, the relative importance of the lower airway exposure 
route and the mucosal exposure route will become evident.
5. Conclusions
This study introduced a method to quantify the administered dose of particles deposited on 
the facial mucosa. A realistic face and airway model that includes a face, an oropharynx, a trachea, 
the first five generations of bronchi, and lung volume was fabricated via CT scanning and 3D A
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printing techniques. By simulating a mouth-breather with 11.0 ± 1.0 L/min continuous inhalation 
airflow, we quantified the administered dose as monodispersed fluorescent particles released from 
an incoming jet located 0.2 m from the nose.
Approximately 1.0% to 2.0% of the released micron-sized particles were deposited on the 
model’s eyes and lips, and 0.6-μm, 3.0-μm, and 5.0-μm particles showed higher deposition rates 
than 1.0-μm and 2.0-μm particles. More than 80% of the total administered dose was deposited on 
the facial mucosa rather than on the eyes. Our in vitro realistic face and airway model does not 
include the biological features of real human subjects, but it can help to quantify the administered 
dose of particles with decent accuracy. This method is a convenient and economical means to test 
safety zones and protection methods with actual doses from a nearby pollutant source. 
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Tables
Table 1 Experimental parameters.
Particle diameter 
(μm)
Density 
(kg/m3) Exposure time (min) Breath type
Flow rate 
(L/min)
0.6 50
1.0 40
2.0 1530 30 11.0 ± 1.0 
3.0 20
5.0 10
Mouth-breath
er
Table 2 Relationship between L/W and fluorescence intensity .∆𝐼
L/W 0.0 0.1 0.2 0.4 0.8
Amador (2015)33
(10-μm droplets, 
Re = 500-1000)
1.0 ± 0.2 0.8 ± 0.1 0.4 ± 0.2 0.8 ± 0.1 1.2 ± 0.2
∆𝐼
Current study
(0.6-µm to 5-μm 
particles, Re = 
1500, 
W = 26.74 mm)
Face and 
airway 
model
Animal
Animal and human
L = 8 to 12 mm34; L/W = 0.3 to 
0.5;
 = 0.6 to 0.9∆𝐼
Animal
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Figure legends
Fig. 1. Segmentation process of computed tomographic images. a: single slice of computed 
tomographic scan; b: segmented face, nasal, throat, airway, and lung volumes; and c: 
completed realistic face and airway model.
Fig. 2. Three-dimensional printed in vitro face and airway model.
Fig. 3. Experimental setup for human exposure assessment.
Fig. 4. Fluorescence intensity–mass concentration standard curves in various concentration 
distributions.
Fig. 5. Benchmark measurement of fluorescence on blank surfaces and within pure water droplets.
Fig. 6. Background fluorescence intensity measurement.
Fig. 7. Total mass of generated particles for various particle sizes.
Fig. 8. Mucosal deposition rate versus particle size [mucosal administered dose (g) / generated 
particle mass (g)]
Fig. 9. Administered dose index versus particle size.
Fig. 10. Deposition percentage for particles of various diameters with and without inhaled airflow. 
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